Publications by authors named "Matthew Lardy"

Claim this Profile
T
The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations.
Eranga R Balasooriya, Qibiao Wu, Haley Ellis, Yuanli Zhen, Bryanna L Norden, Matthew Lardy

Clin Cancer Res· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of KIN-3248, An Irreversible, Next Generation FGFR Inhibitor for the Treatment of Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations.
John S Tyhonas, Lee D Arnold, Jason M Cox, Aleksandra Franovic, Elisabeth Gardiner, Matthew Lardy

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational discovery of a highly novel and selective mTOR inhibitor.
Stanley Jin, Satoshi Mikami, Nick Scorah, Young Chen, Petro Halkowycz, Matthew Lardy

Bioorg Med Chem Lett· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disarming Pseudomonas aeruginosa virulence factor LasB by leveraging a Caenorhabditis elegans infection model.
Jie Zhu, Xiaoqing Cai, Tyler L Harris, Major Gooyit, Malcolm Wood, Matthew Lardy

Chem Biol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis/biological evaluation of hydroxamic acids and their prodrugs as inhibitors for Botulinum neurotoxin A light chain.
Hajime Seki, Sabine Pellett, Peter Silhár, G Neil Stowe, Beatriz Blanco, Matthew A Lardy

Bioorg Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.
Peter Silhár, Matthew A Lardy, Mark S Hixon, Charles B Shoemaker, Joseph T Barbieri

ACS Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Illuminator: increasing synergies between medicinal and computational chemists.
Alberto Gobbi, Matthew Lardy, Sun Hee Kim, Frank Ruebsam, Martin Tran

In Silico Biol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Building a three-dimensional model of CYP2C9 inhibition using the Autocorrelator: an autonomous model generator.
Matthew A Lardy, Laurie Lebrun, Drew Bullard, Charles Kissinger, Alberto Gobbi

J Chem Inf Model· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and molecular modeling provide insight into a Pseudomonas aeruginosa quorum sensing conundrum.
Joseph S Zakhari, Isao Kinoyama, Anjali K Struss, Prasanna Pullanikat, Colin A Lowery, Matthew Lardy

J Am Chem Soc· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymerase.
David A Ellis, Julie K Blazel, Chinh V Tran, Frank Ruebsam, Douglas E Murphy, Matthew Lardy

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.
David A Ellis, Julie K Blazel, Stephen E Webber, Chinh V Tran, Peter S Dragovich, Matthew Lardy

Bioorg Med Chem Lett· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda6-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones: Part 4. Optimization of DMPK properties.
Maria V Sergeeva, Yuefen Zhou, Darian M Bartkowski, Thomas G Nolan, Daniel A Norris, Matthew Lardy

Bioorg Med Chem Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase.
Frank Ruebsam, Stephen E Webber, Martin T Tran, Chinh V Tran, Douglas E Murphy, Matthew Lardy

Bioorg Med Chem Lett· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hydra: a self regenerating high performance computing grid for drug discovery.
Drew Bullard, Alberto Gobbi, Matthew A Lardy, Charles Perkins, Zach Little

J Chem Inf Model· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis